Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2013
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639662/
https://ncbi.nlm.nih.gov/pubmed/23634291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.71
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items